Providone-Iodine

DRUG2 trials

Sponsors

iRenix Medical, Inc.

Conditions

Retinal Disease

Phase 2

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

CompletedNCT05747430

iRenix Medical, Inc.Retinal Disease

Start: 2023-02-22End: 2026-03-31Updated: 2026-04-03

Phase 3

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Not yet recruitingNCT05750589

iRenix Medical, Inc.Retinal Disease

Start: 2026-09-01End: 2027-12-31Target: 240Updated: 2026-04-03